What is the NOAEL for Nitrofurazone?
Nitrofurazone has 100 NOAEL studies in the database. The lowest reported value is 0.5 ug/day. Source: California Proposition 65.
NOAEL Data
IARC Group 3
Prop 65
Cosmetic Ingredient
Nitrofurazone
Also known as: 5-Nitro-2-furaldehyde semicarbazone, Hydrazinecarboxamide, 2-[(5-nitro-2-furanyl)methylene]-, 2-Furancarboxaldehyde, 5-nitro-,semicarbazone, Actin-N, Becafurazone (+15 more)
CAS 59-87-0
Nitrofurazone (CAS 59-87-0) is a chemical substance; key hazard signal: IARC Group 3. Key regulatory status: California Proposition 65, 6 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, IARC, CA Prop 65.
SOURCE
noael studies public
NOAEL studies
100
SOURCE
chemical inventory jurisdictions
Regulatory lists
6
SOURCE
eu clp annex vi
GHS signal
Not classified
Chemical Identity
CAS, identifiers, formula, and alternate names for the matched substance record.
SOURCE
DSSTox identifiers
26 fields
Name
Nitrofurazone
CAS Number
59-87-0
DTXSID
DTXSID5020944
Molecular Formula
C6H6N4O4
InChI Key
IAIWVQXQOWNYOU-UHFFFAOYSA-N
Monoisotopic Mass
198.038905
Synonyms
5-Nitro-2-furaldehyde semicarbazoneHydrazinecarboxamide, 2-[(5-nitro-2-furanyl)methylene]-2-Furancarboxaldehyde, 5-nitro-,semicarbazoneActin-NBecafurazoneBiofuracinaBiofureaBRN 0086403CocafurinDermofuralDynazoneEINECS 200-443-1
IARC Carcinogen Classification
Carcinogenic hazard classification from IARC monograph evaluations.
SOURCE
IARC Monographs on the Identification of Carcinogenic Hazards to Humans
1 records
| Group | Meaning | Evaluated | Volume |
|---|---|---|---|
| Group 3 | Not classifiable | 1989 | 50 |
California Proposition 65
California OEHHA listing status and toxicity category.
SOURCE
California OEHHA Proposition 65 List
1 records
| Chemical | Toxicity Type | Cancer | Developmental | Listed |
|---|---|---|---|---|
| - | cancer | Yes | No | - |
Functional Uses
Industrial and product-use categories associated with this substance.
SOURCE
EPA CPDat
1 records
Biocide
Regulatory Lists
Inventory, screening, and regulatory list matches from public chemical databases.
SOURCE
EPA CPDat
6 records
| List | Keyword | Source |
|---|---|---|
| pharmaceutical | US International Trade Commission | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Canada; pharmaceutical | DrugBank | DrugBank |
| active_ingredient; Australia | Australian Pesticides and Veterinary Medicines Authority | CPCat |
| OEHHA Proposition 65 (3/2019) | STATE OF CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY | OEHHA Proposition 65 List |
| OEHHA Proposition 65 (1/2023) | California Office of Environmental Health Hazard Assessment | OEHHA Proposition 65 List |
NOAEL Studies
Toxicology endpoints rendered from public NOAEL study rows.
SOURCE
NOAEL studies
Showing 50 of 100 studies
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| AB0.5 | ug/day | California Proposition 65 NSRL | - | - | California Proposition 65 |
| AB0.5 | ug/day | California Proposition 65 NSRL | - | - | California Proposition 65 |
| AB0.5 | ug/day | California Proposition 65 NSRL | - | - | California Proposition 65 |
| AB0.5 | ug/day | California Proposition 65 NSRL | - | - | California Proposition 65 |
| ABcancer | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| ABcancer | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| ABcancer | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| ABcancer | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| - | uL/min/10^6 cells | Clint | - | Human | NTP_ICE_adme_parameters |
| 0.4167 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.93 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 1.786 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 1.875 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 2.143 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 2.2 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 2.475 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 3 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 12 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 31.25 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 99 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 150 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.2 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.3333 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.5 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.8333 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 1.429 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 2 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 2.5 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 10 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 20 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 25 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| X8XI70B5Z6 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| X8XI70B5Z6 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| X8XI70B5Z6 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| X8XI70B5Z6 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 0.856 | fraction | Fu | - | Human | NTP_ICE_adme_parameters |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | unitless | IARC group | - | - | NTP_ICE_cancer |
| - | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.6667 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 1.01 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 1.075 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 4.167 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 8 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 16.67 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 22.73 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 28 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 58.33 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 60 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 66.67 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
Showing 50 of 100 studies
Cosmetic Safety Profile
Same-CAS cosmetic ingredient record for cross-vertical context.
SOURCE
CosIng / Ingredients DB
EU Status
permitted
Max
-
Category
Preservatives
Pharmaceutical Data
Same-CAS pharmaceutical records from drug and bioactivity sources.
SOURCE
EMBL-EBI ChEMBL
NITROFURAZONE
ChEMBL Phase
4
Adverse Events
1538
Bioactivity
9
Cannabis Data
Same-CAS cannabis compliance and lab records where available.
SOURCE
Cannabis regulatory / lab data
efsa substances
1 cannabis record found in efsa substances.
View full cannabis profile →Frequently Asked Questions
What regulatory lists include Nitrofurazone?
Nitrofurazone appears on 5 regulatory/inventory lists including pharmaceutical, Canada; pharmaceutical, active_ingredient; Australia, and 2 more. Source: EPA CPDat.
Is Nitrofurazone a carcinogen according to IARC?
Nitrofurazone is classified by IARC as Group 3 — not classifiable as to its carcinogenicity to humans (evaluated 1989). Source: IARC Monographs on the Identification of Carcinogenic Hazards to Humans.
Is Nitrofurazone on the California Proposition 65 list?
Yes, Nitrofurazone is listed under California Proposition 65 for cancer. Source: California OEHHA Proposition 65.
Is Nitrofurazone used in cosmetics?
Yes, Nitrofurazone is also indexed as a cosmetic ingredient under the name NITROFURAZONE. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Where does the safety data for Nitrofurazone come from?
Safety data is sourced from EPA ToxValDB, EPA CPDat, EPA DSSTox, IARC Monographs, California Proposition 65, CosIng / Ingredients DB, ChEMBL / DailyMed, cannabis regulatory/lab databases. All data traces to primary regulatory sources and is updated from official government databases.
Is Nitrofurazone used outside industrial chemicals?
Nitrofurazone also appears in cosmetics, pharmaceutical, cannabis databases.